Only one breast cancer patient with FGFR1-amplified showed tumor regression, and partial responses were reported in FGFR3-mutated bladder cancer, while in one patient with hepatocellular carcinoma (HCC) and in one patient with cholangiocarcinoma (CCA), both with FGFR2-BICC1 (bicaudal C homolog 1) fusion gene, tumor shrinkage was observed [155]. Here, FGFR2 is linked to cholangiocarcinoma.